CRAWLEY, England, July 19, 2013 /PRNewswire/ -- Elekta has received CE marking for its Clarity® 4D Monitoring system permitting European clinics to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate with sub millimeter accuracy during the delivery of therapeutic radiation beams.
The ability to continuously visualize the prostate and surrounding anatomy during treatment is especially important for clinicians pursuing advanced prostate protocols, such as reduced margin hypofractionated therapy or advanced stereotactic ablative body radiotherapy (SABR).
Continuous target visualization
4D monitoring of the prostate with Clarity during treatment offers continuous tracking of the target and imaging of the surrounding anatomy, including the bladder, rectum and penile bulb. Clinicians are keen to avoid this surrounding anatomy to minimize the chance of side effects of treatment such as erectile dysfunction, incontinence or rectal bleeding. Being able to visualize these structures during treatment could potentially enable clinicians to create plans with tighter margins around intended targets, thereby minimizing radiation exposure to healthy tissue.
Clarity 4D Monitoring uses Autoscan acquisition technology to robotically acquire live transperineal ultrasound images of soft tissue anatomy. This comfortable, non-invasive imaging procedure does not involve any extra radiation dose to the patient and does not require the use of implanted markers.
Cancer patients at Hopital Riviera (Vevey, Switzerland) will soon benefit from the custom technology configuration of their newly acquired Versa HD™ radiotherapy system and Clarity 4D Monitoring system.
"We are committed to offering the most advanced technologies to our patients, which is why we chose Elekta's Versa HD solution, including Clarity 4D Monitoring for prostate. We will use this system for transperineal imaging of the prostate to align the daily treatment with the prostate's position and eventually monitor that position during treatment. This represents a substantial step forward in treating patients and we look forward to using the technology," says Oscar Matzinger, M.D., radiation oncologist at Hopital Riviera and Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland).
Physicians at Torino, Italy's University Hospital of Turin also are looking forward to improving prostate tracking with Clarity 4D Monitoring.
"Intra-fractional motion management will continue to increase in importance as more sophisticated methods of treating the prostate gain acceptance," says Umberto Ricardi, M.D., radiation oncologist at the center. "Clarity 4D Monitoring will be an important component in realizing the potential these protocols offer us as clinicians."
Learn more at www.elekta.com/clarity.
Versa HD is not for sale or distribution in all markets.
For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: firstname.lastname@example.org
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: email@example.com
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Copyright©2012 PR Newswire.
All rights reserved